FIH to NDA in 5 Years, The Calistoga Pharmaceuticals Story


Thursday, September 18, 2014

Location:

University of Michigan North Campus Research Complex
2800 Plymouth Rd.
Building 10 - Research Auditorium
Ann Arbor, Michigan  48105

Networking: 5:00 pm

Program: 6:00 pm

Register Now


Featured Guest Speaker:

Carol Gallagher, PharmD, Former CEO of Calistoga Pharmaceuticals


Zydelig (idelalisib), a first-in-class, selective, PI3K-delta inhibitor, was recently approved by the FDA for three indications to treat relapsed and/or refractory SLL, CLL or indolent NHL patients. Zydelig is marketed by Gilead Sciences. Gilead Sciences acquired Zydelig through their acquisition of Calistoga Pharmaceuticals in 2011.
 
Kicking off BioArbor’s Fall 2014 season, Dr. Carol Gallagher, past CEO of Calistoga Pharmaceuticals will present the story of the development of Zydelig and the formation and successful exit of Calistoga Pharmaceuticals. Come hear her drug development and venture-backed company development perspectives through the case study of Calistoga Pharmaceuticals and Zydelig.  Founded by Mike Gallatin and Jamie Topper from Frazier Healthcare, Calistoga Pharmaceuticals was initially financed in 2007 based on a set of novel, preclinical assets spun out of Icos Pharmaceuticals. Dr. Gallagher together with an experienced team she helped to build, advanced a first-in-class PI3K inhibitor idelalisib through definitive, proof-of-concept studies in patients with certain lymphomas and leukemias. These efforts ultimately led to the acquisition of Calistoga by Gilead Sciences in 2011 for a total consideration of $600 million.  Join us for this special BioArbor session!

About Carol Gallagher:

An industry veteran with more than 25 years of experience in commercial, drug development and business development roles at large and small biopharmaceutical companies, Dr. Gallagher is the past president and CEO of Calistoga Pharmaceuticals. More recently, she has worked in venture capital as a Venture Partner at Frazier Healthcare Ventures and served on the boards of several companies including Aragon Pharmaceuticals, acquired by Johnson and Johnson in 2012, and currently Atterocor, AnaptysBio, Atara Bio and eFFECTOR Therapeutics.
 
During her tenure as CEO at Calistoga, Dr. Gallagher raised $80 million in venture financing and advanced the company's lead molecule, CAL-101 (now called Zydelig) into full development, securing a successful exit with the $600 million acquisition by Gilead Sciences in April 2011. Gallagher began her career in sales and marketing at Eli Lilly in 1989 and also held various commercial and development roles at Amgen, Agouron Pharmaceuticals, Pfizer, CancerVax and Anadys. Notable during her career was her role as the Rituxan Development Team Leader at Idec Pharmaceuticals and after the merger, Biogen Idec.

Dr. Gallagher attended Vanderbilt University and holds BS and PharmD degrees from the College of Pharmacy at the University of Kentucky.



SPONSORS

       

 

 

 

 

 

 


University of Michigan Venture Center